{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:00:42Z","timestamp":1788454842379,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:00:00Z","timestamp":1759017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J01600"],"award-info":[{"award-number":["2023J01600"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2023Y9038"],"award-info":[{"award-number":["2023Y9038"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2023CXA017"],"award-info":[{"award-number":["2023CXA017"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejps.2025.107301","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:43:39Z","timestamp":1759297419000},"page":"107301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants"],"prefix":"10.1016","volume":"215","author":[{"given":"Peilin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenming","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinfang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuihong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107301_bib0002","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(13)60084-7","article-title":"Tuberculosis in London: not unexpected","volume":"381","author":"Anderson","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2025.107301_bib0003","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0890334414566237","article-title":"Transfer of natalizumab into breast milk in a mother with multiple sclerosis","volume":"31","author":"Baker","year":"2015","journal-title":"J. Hum. Lact."},{"key":"10.1016\/j.ejps.2025.107301_bib0004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/14760584.2019.1599286","article-title":"In utero exposure to biologic disease-modifying anti-rheumatic drugs and effects to the infant: infectious complications, vaccine response, and safety of live vaccine administration","volume":"18","author":"Berkhout","year":"2019","journal-title":"Expert. Rev. Vaccines."},{"key":"10.1016\/j.ejps.2025.107301_bib0005","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3389\/fmed.2020.00336","article-title":"Infections in the era of targeted therapies: mapping the road ahead","volume":"7","author":"Calabrese","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.ejps.2025.107301_bib0006","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221150040","article-title":"Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis","volume":"16","author":"Callegari","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.ejps.2025.107301_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.6345","article-title":"Vaccine safety and immunogenicity in patients with multiple sclerosis treated with Natalizumab","volume":"7","author":"Carvajal","year":"2024","journal-title":"JAMa Netw. Open."},{"key":"10.1016\/j.ejps.2025.107301_bib0008","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/s41591-019-0568-2","article-title":"A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients","volume":"25","author":"Cassotta","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejps.2025.107301_bib0009","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/cpt.3031","article-title":"Physiologically-based pharmacokinetic modeling of anti-tumor necrosis factor agents for inflammatory bowel disease patients to predict the withdrawal time in pregnancy and vaccine time in infants","volume":"114","author":"Chen","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107301_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00363","article-title":"Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: a propensity-matched study","volume":"21","author":"Chisari","year":"2024","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.ejps.2025.107301_bib0011","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000723","article-title":"Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis Optica spectrum disorder","volume":"7","author":"Ciplea","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ejps.2025.107301_bib0012","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-024-12608-6","article-title":"Pharmacogenomics of clinical response to Natalizumab in multiple sclerosis: a genome-wide multi-centric association study","author":"Clarelli","year":"2024","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejps.2025.107301_bib0013","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(12)61401-9","article-title":"Breathlessness, night sweats, and weight loss on natalizumab","volume":"380","author":"Dahdaleh","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2025.107301_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241260977","article-title":"Neuroaxonal damage in natalizumab-treated MS patients: the role of JCV antibody titres","author":"Dalla Costa","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0015","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s40262-017-0538-0","article-title":"Physiologically based pharmacokinetic modeling of renally cleared drugs in pregnant women","volume":"56","author":"Dallmann","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107301_bib0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10928-023-09849-9","article-title":"Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules","volume":"50","author":"de Witte","year":"2023","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2025.107301_bib0017","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1212\/NXI.0000000000000388","article-title":"alpha4-integrin receptor desaturation and disease activity return after natalizumab cessation","volume":"4","author":"Derfuss","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ejps.2025.107301_bib0018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/13524585211069922","article-title":"Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: a clinical commentary","volume":"28","author":"Dobson","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0019","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: 'Association of British Neurologists' guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pr. Neurol."},{"key":"10.1016\/j.ejps.2025.107301_bib0020","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejps.2025.107301_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200321","article-title":"Pharmacokinetics and pharmacodynamics of Natalizumab 6-week dosing vs continued 4-week dosing for relapsing-remitting multiple sclerosis","volume":"11","author":"Foley","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ejps.2025.107301_bib0022","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1586\/14737175.2014.962517","article-title":"How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis?","volume":"14","author":"Fragoso","year":"2014","journal-title":"Expert. Rev. NeurOther"},{"key":"10.1016\/j.ejps.2025.107301_bib0023","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1208\/s12248-022-00722-0","article-title":"Opportunities and challenges for PBPK model of mAbs in paediatrics and pregnancy","volume":"24","author":"Gill","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2025.107301_bib0024","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ecco-jcc\/jjad005","article-title":"Vaccines in children exposed to biological agents In utero and\/or during breastfeeding: are they effective and safe?","volume":"17","author":"Gisbert","year":"2023","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ejps.2025.107301_bib0025","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13052-021-01025-4","article-title":"Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy","volume":"47","author":"Godano","year":"2021","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ejps.2025.107301_bib0026","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1093\/rheumatology\/keac141","article-title":"A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero","volume":"61","author":"Goulden","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejps.2025.107301_bib0027","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/cpt.2815","article-title":"Physiologically-based pharmacokinetic modeling of Omalizumab to predict the pharmacokinetics and pharmacodynamics in pediatric patients","volume":"113","author":"Guo","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2025.107301_bib0028","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/jnnp-2023-331525","article-title":"Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis","volume":"95","author":"Haben","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejps.2025.107301_bib0029","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.ejps.2025.107301_bib0030","first-page":"1144","article-title":"Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling","volume":"10","author":"Hardiansyah","year":"2018","journal-title":"MAbs."},{"key":"10.1016\/j.ejps.2025.107301_bib0031","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1177\/1352458512441688","article-title":"Prediction of antibody persistency from antibody titres to natalizumab","volume":"18","author":"Jensen","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0032","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology."},{"key":"10.1016\/j.ejps.2025.107301_bib0033","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13311-022-01224-9","article-title":"Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management","volume":"19","author":"Krajnc","year":"2022","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.ejps.2025.107301_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11940-021-00666-4","article-title":"Treatment of women with multiple sclerosis planning pregnancy","volume":"23","author":"Krysko","year":"2021","journal-title":"Curr. Treat. Options. Neurol."},{"key":"10.1016\/j.ejps.2025.107301_bib0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejps.2025.107301_bib0036","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000769","article-title":"Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases","volume":"7","author":"LaHue","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.ejps.2025.107301_bib0037","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1177\/13524585231204121","article-title":"Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: a case series","volume":"29","author":"Lapucci","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0038","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejps.2025.107301_bib0039","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s40262-020-00977-w","article-title":"Physiologically based pharmacokinetic modeling framework to predict neonatal pharmacokinetics of transplacentally acquired emtricitabine, Dolutegravir, and Raltegravir","volume":"60","author":"Liu","year":"2021","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2025.107301_bib0040","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/ecco-jcc\/jjac093","article-title":"Timing of live attenuated vaccination in infants exposed to Infliximab or Adalimumab in Utero: a prospective cohort study in 107 children","volume":"16","author":"Liu","year":"2022","journal-title":"J. Crohns. Colitis."},{"key":"10.1016\/j.ejps.2025.107301_bib0041","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1080\/19420862.2018.1506648","article-title":"A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: effects of K(on), K(off), endosome trafficking, and animal species","volume":"10","author":"Maas","year":"2018","journal-title":"MAbs."},{"key":"10.1016\/j.ejps.2025.107301_bib0042","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/17425255.2018.1482278","article-title":"Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies","volume":"14","author":"Malik","year":"2018","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejps.2025.107301_bib0043","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/jcph.1540","article-title":"Integration of ontogeny into a physiologically based pharmacokinetic model for monoclonal antibodies in premature infants","volume":"60","author":"Malik","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107301_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134236","article-title":"Three doses of COVID-19 vaccines: a retrospective study evaluating the safety and the immune response in patients with multiple sclerosis","volume":"12","author":"Maniscalco","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejps.2025.107301_bib0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jneuroim.2011.12.009","article-title":"Latent tuberculosis seems not to reactivate in multiple sclerosis patients on natalizumab","volume":"243","author":"Mulero","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ejps.2025.107301_bib0046","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(13)60085-9","article-title":"Tuberculosis in London: not unexpected - authors' reply","volume":"381","author":"Nicholas","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2025.107301_bib0047","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10928-017-9559-4","article-title":"A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim","volume":"45","author":"Niederalt","year":"2018","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2025.107301_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219345","article-title":"AGT haplotype in ITGA4 gene is related to antibody-mediated rejection in heart transplant patients","volume":"14","author":"N\u00fa\u00f1ez","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2025.107301_bib0049","doi-asserted-by":"crossref","DOI":"10.7326\/AITC202106150","article-title":"Multiple sclerosis","volume":"174","author":"Olek","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejps.2025.107301_bib0050","article-title":"Family planning in fertile-age patients with multiple sclerosis (MS) (ConPlanEM Study): delphi consensus statements","volume":"15","author":"Oreja-Guevara","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.ejps.2025.107301_bib0051","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1208\/s12248-020-00460-1","article-title":"Development and application of a physiologically-based pharmacokinetic model to predict the pharmacokinetics of therapeutic proteins from full-term neonates to adolescents","volume":"22","author":"Pan","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2025.107301_bib0052","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1651-2227.1973.tb08100.x","article-title":"Simultaneous determination of plasma volume and transcapillary escape rate with 131 I-labelled albumin and T-1824 in the newborn","volume":"62","author":"Parving","year":"1973","journal-title":"Acta Paediatr. Scand."},{"key":"10.1016\/j.ejps.2025.107301_bib0053","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40120-023-00440-5","article-title":"Real-world effectiveness of Natalizumab extended interval dosing in a French cohort","volume":"12","author":"Pelle","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.ejps.2025.107301_bib0054","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41372-022-01528-w","article-title":"Immunoglobulin G and subclasses placental transfer in fetuses and preterm newborns: a systematic review","volume":"43","author":"Pereira","year":"2023","journal-title":"J. Perinatol."},{"key":"10.1016\/j.ejps.2025.107301_bib0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/1744666X.2019.1561282","article-title":"From mother to baby: antenatal exposure to monoclonal antibody biologics","volume":"15","author":"Pham-Huy","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.ejps.2025.107301_bib0056","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.707","article-title":"A randomized trial evaluating various administration routes of Natalizumab in multiple sclerosis","volume":"56","author":"Plavina","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107301_bib0057","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1177\/13524585221079598","article-title":"Natalizumab treatment and pregnancy in multiple sclerosis: a reappraisal of maternal and infant outcomes after 6 years","volume":"28","author":"Portaccio","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0058","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/psp4.12927","article-title":"The quest for balance between capturing data and model complexity: a quantitative clinical pharmacology approach applied to monoclonal antibodies","volume":"12","author":"Pressly","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107301_bib0059","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.715195","article-title":"Drug and neurofilament levels in serum and breastmilk of women with multiple sclerosis exposed to Natalizumab during pregnancy and lactation","volume":"12","author":"Proschmann","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2025.107301_bib0060","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1177\/1352458517728813","article-title":"Natalizumab during pregnancy and lactation","volume":"24","author":"Proschmann","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105632","article-title":"Latent tuberculosis prevalence, diagnosis and treatment in Multiple Sclerosis as a strategy for reducing infection reactivation during immunosuppressant therapy","volume":"86","author":"Reis","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.ejps.2025.107301_bib0062","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/1352458511431073","article-title":"Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped","volume":"18","author":"Rispens","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0063","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"14","key":"10.1016\/j.ejps.2025.107301_bib0064","article-title":"Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability","volume":"2","author":"Sarin","year":"2010","journal-title":"J. Angiogenes. Res."},{"key":"10.1016\/j.ejps.2025.107301_bib0065","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.thromres.2011.10.023","article-title":"The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives","volume":"129","author":"Schlesinger","year":"2012","journal-title":"Thromb. Res."},{"issue":"164","key":"10.1016\/j.ejps.2025.107301_bib0066","article-title":"New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies","volume":"13","author":"Sehr","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.ejps.2025.107301_bib0067","first-page":"16","article-title":"Disease-modifying therapies (DMTs) in pregnant and lactating women with multiple sclerosis: analysis of real-world data from EudraVigilance database","author":"Sportiello","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejps.2025.107301_bib0068","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1177\/1352458518813657","article-title":"Therapeutic drug monitoring of natalizumab","volume":"25","author":"Tanaka","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0069","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/jnnp-2023-332804","article-title":"Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy","volume":"95","author":"Thiel","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejps.2025.107301_bib0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/13524585211052168","article-title":"Natalizumab concentrations during pregnancy in three patients with multiple sclerosis","volume":"28","author":"Toorop","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0071","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1161\/HYPERTENSIONAHA.112.199125","article-title":"Influence of growth during infancy on endothelium-dependent vasodilatation at the age of 6 months","volume":"60","author":"Touwslager","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejps.2025.107301_bib0072","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jpeds.2014.11.059","article-title":"Growth and endothelial function in the first 2 years of life","volume":"166","author":"Touwslager","year":"2015","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ejps.2025.107301_bib0073","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1177\/13524585211003020","article-title":"A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis","volume":"27","author":"Trojano","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0074","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1177\/1352458517708464","article-title":"The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing","volume":"24","author":"van Kempen","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.ejps.2025.107301_bib0075","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1212\/WNL.0000000000009995","article-title":"Personalized extended interval dosing of natalizumab in MS: a prospective multicenter trial","volume":"95","author":"van Kempen","year":"2020","journal-title":"Neurology."},{"key":"10.1016\/j.ejps.2025.107301_bib0076","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","article-title":"Pregnancy and multiple sclerosis: an update","volume":"33","author":"Varyte","year":"2021","journal-title":"Curr. Opin. Obs. Gynecol."},{"key":"10.1016\/j.ejps.2025.107301_bib0077","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/1061186X.2013.875030","article-title":"Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering","volume":"22","author":"Wang","year":"2014","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2025.107301_bib0078","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/14712598.2023.2290530","article-title":"Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial","volume":"23","author":"Wessels","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ejps.2025.107301_bib0001","first-page":"5","article-title":"Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89. 2002","volume":"32","author":"ICRP","year":"2002","journal-title":"Ann. ICRP"}],"updated-by":[{"DOI":"10.1016\/j.ejps.2025.107420","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000}},{"DOI":"10.1016\/j.ejps.2025.107420","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000}}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725002994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725002994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T09:39:09Z","timestamp":1768729149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725002994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":78,"alternative-id":["S0928098725002994"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107301","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107301","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107301"}}